|
INBRX-106 Clinical Trials
1 actively recruiting trial across 1 location
No change since May 2026
Also known as: Hexavalent OX40 agonist antibody
Pipeline
Phase 2: 1
Top Sponsors
- Providence Health & Services1
Indications
- Triple Negative Breast Cancer1
- Breast Cancer1
- Cancer1
Los Angeles, California1 trial
Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients
Ellison Institute of Technology (EITM)
Phase 2
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.